- Home
- Apac Syndromic Multiplex Diagnostic Market
APAC Syndromic Multiplex Diagnostic Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-511 | No of pages: 196 | Format:
The Asia-Pacific syndromic multiplex diagnostic market is projected to register a substantial CAGR of 9.6% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2020, and the forecast period is 2022 to 2029
Market Segmentation:
Asia-Pacific Syndromic Multiplex Diagnostic Market - By Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others), Panels Type (Respiratory Panel, GI-Enteric Panel, SexuallyTransmitted Disease Panel, Blood-Sepsis Panel, Meningitis panel and Others), End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others), Country (China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippine, Rest of Asia-Pacific) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of Asia-Pacific syndromic multiplex diagnostic market are:
Increase in prevalence of infectious diseases
Increasing awareness towards early diagnosis
Market Players:
The major companies which are dealing in the Asia-Pacific syndromic multiplex diagnostic are listed below:
BioFire Diagnostics (A Subsidiary of bioMrieux SA)
Seegene Inc.
Luminex Corporation. A DiaSorin Company
F. Hoffmann-La Roche Ltd
BD
Bio-Rad Laboratories, Inc.
Cepheid (A Subsidiary of Danaher)
QIAGEN
Abbott
Hologic, Inc.
Thermo Fisher Scientific Inc.
Siemens Healthcare GmbH
Biocartis
QuantuMDx Group Ltd.
Prominex Inc.
Curetis (A Subsidiary of OpGen, Inc.)
MiRXES Pte Ltd.
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 27 1.1 OBJECTIVES OF THE STUDY 27 1.2 MARKET DEFINITION 27 1.3 OVERVIEW OF ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 27 1.4 LIMITATIONS 29 1.5 MARKETS COVERED 29 2 MARKET SEGMENTATION 32 2.1 MARKETS COVERED 32 2.2 GEOGRAPHICAL SCOPE 33 2.3 YEARS CONSIDERED FOR THE STUDY 34 2.4 CURRENCY AND PRICING 34 2.5 DBMR TRIPOD DATA VALIDATION MODEL 35 2.6 MULTIVARIATE MODELLING 38 2.7 PRODUCT AND SERVICES LIFELINE CURVE 38 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 39 2.9 DBMR MARKET POSITION GRID 40 2.10 MARKET END USER COVERAGE GRID 41 2.11 VENDOR SHARE ANALYSIS 42 2.12 SECONDARY SOURCES 43 2.13 ASSUMPTIONS 43 3 EXECUTIVE SUMMARY 44 4 PREMIUM INSIGHTS 46 4.1 PESTEL ANALYSIS 48 4.2 PORTER'S FIVE FORCES 49 4.3 MARKET SHARE PER PANEL, FOR TOP 3 PLAYERS (2021) 50 5 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: REGULATIONS 51 6 MARKET OVERVIEW 54 6.1 DRIVERS 56 6.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES 56 6.1.2 RISING ADOPTION OF MOLECULAR DIAGNOSTICS TECHNIQUES 57 6.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING 58 6.1.4 INCREASING DEMAND FOR FAST AND ACCURATE DIAGNOSTIC RESULTS 58 6.2 RESTRAINTS 59 6.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS 59 6.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC 59 6.3 OPPORTUNITIES 60 6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 60 6.3.2 RISING DIAGNOSTIC HEALTHCARE EXPENDITURE 60 6.3.3 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCTS 62 6.4 CHALLENGES 63 6.4.1 PRODUCT RECALLS 63 6.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 63 7 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES 64 7.1 OVERVIEW 65 7.2 REAGENTS & CONSUMABLES 68 7.3 INSTRUMENTS, SOFTWARE & ACCESSORIES 68 7.4 SERVICES 69 8 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE 71 8.1 OVERVIEW 72 8.2 VIRAL 75 8.2.1 CORONAVIRUS 76 8.2.2 INFLUENZA VIRUS 76 8.2.3 ADENOVIRUS 76 8.2.4 RHINOVIRUS 76 8.2.5 ROTAVIRUS 76 8.2.6 OTHERS 76 8.3 BACTERIAL 77 8.3.1 PNEUMONIAE 78 8.3.2 BORDETELLA PERTUSSIS 78 8.3.3 STAPHYLOCOCCUS 78 8.3.4 OTHERS 78 8.4 PARASITES 78 8.5 FUNGAL 79 9 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE 81 9.1 OVERVIEW 82 9.2 RESPIRATORY INFECTIONS 85 9.3 GASTROENTERITIS 86 9.4 SEXUALLY TRANSMITTED INFECTIONS 86 9.5 SEPSIS 87 9.6 MENINGITIS 88 9.7 OTHERS 89 10 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE 91 10.1 OVERVIEW 92 10.2 RESPIRATORY PANEL 95 10.3 GI-ENTERIC PANEL 95 10.4 SEXUALLY TRANSMITTED DISEASE PANEL 96 10.5 BLOOD-SEPSIS PANEL 97 10.6 MENINGITIS PANEL 98 10.7 OTHERS 99 11 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER 100 11.1 OVERVIEW 101 11.2 HOSPITALS 104 11.3 CLINICAL LABORATORIES 104 11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 105 11.5 RESEARCH INSTITUTES 106 11.6 OTHERS 107 12 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION 108 12.1 ASIA-PACIFIC 109 12.1.1 CHINA 116 12.1.2 JAPAN 119 12.1.3 INDIA 122 12.1.4 SOUTH KOREA 125 12.1.5 AUSTRALIA 128 12.1.6 SINGAPORE 131 12.1.7 THAILAND 134 12.1.8 MALAYSIA 137 12.1.9 INDONESIA 140 12.1.10 PHILIPPINES 143 12.1.11 REST OF ASIA-PACIFIC 146 13 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY LANDSCAPE 147 13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 147 14 SWOT ANALYSIS 148 15 COMPANY PROFILE 149 15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMRIEUX SA) 149 15.1.1 COMPANY SNAPSHOT 149 15.1.2 REVENUE ANALYSIS 149 15.1.3 COMPANY SHARE ANALYSIS 150 15.1.4 PRODUCT PORTFOLIO 150 15.1.5 RECENT DEVELOPMENTS 151 15.2 F. HOFFMANN-LA ROCHE LTD 152 15.2.1 COMPANY SNAPSHOT 152 15.2.2 REVENUE ANALYSIS 152 15.2.3 COMPANY SHARE ANALYSIS 153 15.2.4 PRODUCT PORTFOLIO 153 15.2.5 RECENT DEVELOPMENT 154 15.3 LUMINEX CORPORATION. A DIASORIN COMPANY 155 15.3.1 COMPANY SNAPSHOT 155 15.3.2 RECENT FINANCIALS 155 15.3.3 COMPANY SHARE ANALYSIS 156 15.3.4 PRODUCT PORTFOLIO 156 15.3.5 RECENT DEVELOPMENT 157 15.4 CEPHEID (A SUBSIDIARY OF DANAHER) 158 15.4.1 COMPANY SNAPSHOT 158 15.4.2 RECENT FINANCIALS 158 15.4.3 COMPANY SHARE ANALYSIS 159 15.4.4 PRODUCT PORTFOLIO 159 15.4.5 RECENT DEVELOPMENTS 160 15.5 QIAGEN 161 15.5.1 COMPANY SNAPSHOT 161 15.5.2 RECENT FINANCIALS 161 15.5.3 COMPANY SHARE ANALYSIS 162 15.5.4 PRODUCT PORTFOLIO 162 15.5.5 RECENT DEVELOPMENT 162 15.6 ABBOTT 163 15.6.1 COMPANY SNAPSHOT 163 15.6.2 REVENUE ANALYSIS 163 15.6.3 PRODUCT PORTFOLIO 164 15.6.4 RECENT DEVELOPMENT 164 15.7 AKONNI BIOSYSTEMS, INC. 165 15.7.1 COMPANY SNAPSHOT 165 15.7.2 PRODUCT PORTFOLIO 165 15.7.3 RECENT DEVELOPMENT 165 15.8 APPLIED BIOCODE, INC. 166 15.8.1 COMPANY SNAPSHOT 166 15.8.2 PRODUCT PORTFOLIO 166 15.8.3 RECENT DEVELOPMENTS 167 15.9 BD 168 15.9.1 COMPANY SNAPSHOT 168 15.9.2 REVENUE ANALYSIS 168 15.9.3 PRODUCT PORTFOLIO 169 15.9.4 RECENT DEVELOPMENTS 169 15.10 BIOCARTIS 170 15.10.1 COMPANY SNAPSHOT 170 15.10.2 REVENUE ANALYSIS 170 15.10.3 PRODUCT PORTFOLIO 171 15.10.4 RECENT DEVELOPMENT 171 15.11 BIO-RAD LABORATORIES, INC. 172 15.11.1 COMPANY SNAPSHOT 172 15.11.2 REVENUE ANALYSIS 172 15.11.3 PRODUCT PORTFOLIO 173 15.11.4 RECENT DEVELOPMENT 173 15.12 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH) 174 15.12.1 COMPANY SNAPSHOT 174 15.12.2 REVENUE ANALYSIS 174 15.12.3 PRODUCT PORTFOLIO 175 15.12.4 RECENT DEVELOPMENT 175 15.13 CURETIS (A SUBSIDIARY OF OPGEN, INC.) 176 15.13.1 COMPANY SNAPSHOT 176 15.13.2 RECENT FINANCIALS 176 15.13.3 PRODUCT PORTFOLIO 177 15.13.4 RECENT DEVELOPMENTS 177 15.14 HOLOGIC, INC. 178 15.14.1 COMPANY SNAPSHOT 178 15.14.2 RECENT FINANCIALS 178 15.14.3 PRODUCT PORTFOLIO 179 15.14.4 RECENT DEVELOPMENT 179 15.15 MIRXES PTE LTD. 180 15.15.1 COMPANY SNAPSHOT 180 15.15.2 PRODUCT PORTFOLIO 180 15.15.3 RECENT DEVELOPMENT 180 15.16 NANMIX, INC. 181 15.16.1 COMPANY SNAPSHOT 181 15.16.2 PRODUCT PORTFOLIO 181 15.16.3 RECENT DEVELOPMENT 181 15.17 PROMINEX INC. 182 15.17.1 COMPANY SNAPSHOT 182 15.17.2 PRODUCT PORTFOLIO 182 15.17.3 RECENT DEVELOPMENT 182 15.18 QUANTUMDX GROUP LTD. 183 15.18.1 COMPANY SNAPSHOT 183 15.18.2 PRODUCT PORTFOLIO 183 15.18.3 RECENT DEVELOPMENTS 183 15.19 SEEGENE INC. 184 15.19.1 COMPANY SNAPSHOT 184 15.19.2 REVENUE ANALYSIS 184 15.19.3 PRODUCT PORTFOLIO 185 15.19.4 RECENT DEVELOPMENTS 188 15.20 SIEMENS HEALTHCARE GMBH 189 15.20.1 COMPANY SNAPSHOT 189 15.20.2 RECENT FINANCIALS 189 15.20.3 PRODUCT PORTFOLIO 190 15.20.4 RECENT DEVELOPMENT 190 15.21 THERMOFISHER SCIENTIFIC INC. 191 15.21.1 COMPANY SNAPSHOT 191 15.21.2 RECENT FINANCIALS 191 15.21.3 PRODUCT PORTFOLIO 192 15.21.4 RECENT DEVELOPMENT 192 16 QUESTIONNAIRE 193 17 RELATED REPORTS 196Segmentation
Short Description Asia-Pacific Syndromic Multiplex Diagnostic Market - By Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others), Panels Type (Respiratory Panel, GI-Enteric Panel, SexuallyTransmitted Disease Panel, Blood-Sepsis Panel, Meningitis panel and Others), End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others), Country (China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippine, Rest of Asia-Pacific) Industry Trends and Forecast to 2029 Market Definition: Syndromic multiplex diagnostic is a type of advanced diagnostic test that is utilised to detect various types of infection diseases such as respiratory infection, infective gastroenteritis, sexually transmitted infections, sepsis, and meningitis, among other types of infectious diseases. Syndromic multiplex diagnostic also helps the clinicians or hospitals to detect the symptoms and signs of the various types of diseases. This lets the health care providers provide the right treatment for the patients and offer more precise outcomes and care that can be performed more quickly. Market Segmentation: The Asia-Pacific syndromic multiplex diagnostic market is categorized into five segments: products and services, infection type, disease, panels type, and end user. Based on products and services, the Asia-Pacific syndromic multiplex diagnostic market is segmented into reagents & consumables, instruments, software & accessories and services Based on infection type, the Asia-Pacific syndromic multiplex diagnostic market is segmented into viral, bacterial, parasites and fungal Based on disease, the Asia-Pacific syndromic multiplex diagnostic market is segmented into respiratory infections, gastroenteritis, sexually transmitted infections, sepsis meningitis and others Based on panels type, the Asia-Pacific syndromic multiplex diagnostic market is segmented into respiratory panel, GI-enteric panel, sexually transmitted disease panel, blood-sepsis panel, meningitis panel and others Based on end user, the Asia-Pacific syndromic multiplex diagnostic market is segmented into clinical laboratories, hospitals, pharmaceutical & biotechnology companies, research institutes and others Market Players The major companies which are dealing in the Asia-Pacific syndromic multiplex diagnostic are listed below: BioFire Diagnostics (A Subsidiary of bioMrieux SA) Seegene Inc. Luminex Corporation. A DiaSorin Company F. Hoffmann-La Roche Ltd BD Bio-Rad Laboratories, Inc. Cepheid (A Subsidiary of Danaher) QIAGEN Abbott Hologic, Inc. Thermo Fisher Scientific Inc. Siemens Healthcare GmbH Biocartis QuantuMDx Group Ltd. Prominex Inc. Curetis (A Subsidiary of OpGen, Inc.) MiRXES Pte Ltd.Methodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.